Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.39 |
| ▸ | LPL | P06858 | 8/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30633731 | 0.89 | PRMT5 (0.38) | PRMT5WDR77LPLLIPGCSF1R | |
| SCHEMBL30633762 | 0.84 | CSF1R (0.38) | PRMT5WDR77LPLLIPGCSF1R | |
| SCHEMBL30633677 | 0.83 | PRMT5 (0.36) | PRMT5WDR77BACE1 | |
| SCHEMBL20045112 | 0.80 | LPL (0.41) | PRMT5WDR77LPLLIPGCSF1R | |
| SCHEMBL30633689 | 0.79 | AKR1B1 (0.37) | PRMT5WDR77CSF1RIRAK4HIF1A | |
| SCHEMBL31558805 | 0.79 | PRMT5 (0.57) | PRMT5WDR77CSF1RBACE1CA1 | |
| SCHEMBL26613873 | 0.79 | PRMT5 (0.41) | PRMT5WDR77CSF1RBACE1HIF1A | |
| SCHEMBL30633729 | 0.77 | PRMT5 (0.34) | PRMT5WDR77CSF1RBACE1IRAK4 | |
| SCHEMBL30633714 | 0.76 | CSF1R (0.37) | PRMT5WDR77LPLLIPGCSF1R | |
| SCHEMBL30633768 | 0.74 | LMNA (0.33) | ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136586-A1 | Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors | BEIGENE, LTD. (KY) | 2025-05-01 | — | — | US | disclosed |
| EP-4514797-A1 | SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | BeiGene, Ltd. (KY) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023208172-A1 | SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | BEIGENE , LTD. (KY) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136586-A1 | Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors | CDK4, CDK7, CDK8 | PRMT5 1462/4885WDR77 1666/4885LPL 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.